AN EMOTION virtual recognition tracking system presented by a group of researchers from Incheon National University, South Korea could pave the way to…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) arose in December 2019 in Wuhan, China, and was noted to cause a severe respiratory distress syndrome termed coronavirus disease (COVID-19)…

The pharmaceutical industry has long struggled with its reputation, but 2020 offered an opportunity for reform. How has their response to the crisis affected perceptions, or is misinformation still getting in the way?

While attention was channelled into COVID-19, patients awaiting other treatments were deprioritised. How can pharma ensure no patients are left behind?

Hear from two thought leaders who share their passion for health economics, their thoughts on non-traditional models, and how they predict drugs will be costed in the future.

COVID-19 has revealed a pandemic of another kind: existing health inequities between population groups. We explore the role and responsibility of medical affairs teams in addressing imbalances and forging a fairer and more inclusive health landscape for the future

What are the obstacles in the way of rolling out precision medicine and how can medical affairs professionals overcome them to fast-track adoption for patients?

What role can medical affairs professionals play in filling this knowledge gap as they communicate the importance of sexual health?

Cyber-attacks have become a mounting threat to the pharmaceutical industry over the past year, putting COVID-19 research data as well as supply and distribution chains at risk. We explore what can pharma learn from more experienced industries as they try to mitigate hacking